Division of Gastroenterology and Hepatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Division of Gastroenterology, University of California Irvine, Irvine, California.
Clin Gastroenterol Hepatol. 2022 Aug;20(8):1739-1747. doi: 10.1016/j.cgh.2021.02.005. Epub 2021 Feb 5.
BACKGROUND & AIMS: Efforts to assess and improve the effectiveness of Barrett's esophagus (BE) screening and surveillance are ongoing in the United States. Currently, there are limited population-based data in the United States to guide these efforts.
We performed a retrospective cohort study using data from large commercial and Medicare Advantage health plans in the United States from 2004 - 2019. We identified individuals with BE and analyzed the proportion who developed EAC. EACs were classified as prevalent EAC (diagnosed within 30 days of index endoscopy), post-endoscopy esophageal adenocarcinoma (PEEC, diagnosed 30 - 365 days after index endoscopy), and incident EAC (diagnosed 365 days or more after index endoscopy). Using this cohort, we performed a nested case-control study to identify factors associated with prevalent EAC at BE diagnosis and study healthcare utilization prior to BE diagnosis.
We identified 50,817 individuals with incident BE. Of the 366 who developed EAC, 67.2%, 13.7%, and 19.1% were diagnosed with prevalent EAC, PEEC, and incident EAC respectively. Factors positively associated with prevalent EAC versus BE without prevalent EAC included male sex, dysphagia, weight loss, and Charlson-Deyo comorbidity score. In those with prevalent EAC, most patients with dysphagia or weight loss had their symptoms first recorded within three months of EAC diagnosis. Healthcare utilization rates were similar between those with and without prevalent EAC.
Two-thirds of EACs among individuals with BE are diagnosed at the time of BE diagnosis. Additionally, PEEC accounts for 14% of these EACs. These results may guide future research studies that investigate novel BE diagnostic strategies that reduce the morbidity and mortality of EAC.
目前,美国正在努力评估和提高 Barrett 食管(BE)筛查和监测的效果。目前,美国针对这些努力的人群数据有限。
我们使用美国大型商业和医疗保险优势健康计划的数据进行了回顾性队列研究。我们确定了 BE 患者,并分析了他们发展为 EAC 的比例。EAC 分为现患 EAC(在指数内镜检查后 30 天内诊断)、内镜后食管腺癌(PEEC,在指数内镜检查后 30-365 天内诊断)和新发 EAC(在指数内镜检查后 365 天或更长时间诊断)。使用该队列,我们进行了一项嵌套病例对照研究,以确定 BE 诊断时现患 EAC 相关的因素,并研究 BE 诊断前的医疗保健利用情况。
我们确定了 50817 例新发 BE 患者。在 366 例发展为 EAC 的患者中,67.2%、13.7%和 19.1%分别诊断为现患 EAC、PEEC 和新发 EAC。与无现患 EAC 的 BE 患者相比,现患 EAC 患者的男性、吞咽困难、体重减轻和 Charlson-Deyo 合并症评分等因素与现患 EAC 呈正相关。在有现患 EAC 的患者中,大多数有吞咽困难或体重减轻的患者,其症状最早在 EAC 诊断前三个月内记录。有现患 EAC 和无现患 EAC 的患者的医疗保健利用率相似。
在 BE 患者中,有三分之二的 EAC 在 BE 诊断时被诊断出来。此外,PEEC 占这些 EAC 的 14%。这些结果可能为未来研究旨在减少 EAC 发病率和死亡率的新型 BE 诊断策略提供指导。